Founded in 1993
  Year: 2013 | Volume: 21 | Issue: 1 | Pages: 17-19
  Review Article
  CD30 – THE HEAD OF TNF-FAMILY…OR A SUCCESSFUL STORY OF BRENTUXIMAB VEDOTIN
Lazar Popovic, Darjana Jovanovic, ?orde Popovic
  DOI: 10.2298/AOO1301017P
  Abstract:
  Hodgkin lymphoma and anaplastic large cell lymphoma are malignancies that highly express CD30 antigen on the cell surface. Both are generally curable by standard chemotherapy but refractory diseases and relapses are treatment problems. Brentuximab-vedotin is a labeled monoclonal antibody against CD30 and it is approved for the treatment of Hodgkin lymphoma relapsed after autologous stem cell transplantation and for relapsed anaplastic large cell lymphoma. This is the first drug approved for the treatment of Hodgkin lymphoma after 30 years.
  Key words: Hodgkin Disease; Antigens, CD30; Antineoplastic Agents; Antibodies, Monoclonal; Lymphoma, Large Cell, Anaplastic; Hematopoietic Stem Cell Transplantation
  Read full text in PDF [Full Text]
Next article

Previous article

Table of contents

Browse all Volumes

Search all Volumes
By keywords
By authors

  Search AoO for:
 

  Related articles in AoO:
 
About Journal | Editorial Board | Editorial Policy | Instructions for Authors | Open Access | Advertising | Payed issues | Article Submission Charge | Contact
Founder, owner and publisher: Oncology Institute of Vojvodina, Serbia
Online since 1997 (Abstracts only); 2000 (Abstracts and Full text)
ISSN: 0354-7310 eISSN: 1450-9520